ALV1

Background Introduction

ALV1 is a novel small-molecule ligand designed to target the von Hippel-Lindau (VHL) E3 ubiquitin ligase complex. As one of the most commonly used E3 ligase recruiting elements in PROTAC (Proteolysis Targeting Chimera) research, VHL ligands like ALV1 enable precise and efficient degradation of disease-relevant proteins. The structural optimization of ALV1 provides improved solubility, high selectivity, and increased stability, facilitating its use for next-generation targeted protein degradation applications.

Mechanism

ALV1 functions as a VHL E3 ligase ligand by specifically binding to the VHL protein component of the CUL2-VHL complex. When incorporated into PROTACs, ALV1 mediates the recruitment of VHL to a target protein via a bifunctional linker, promoting the ubiquitination and subsequent proteasomal degradation of the target. Its optimized structure ensures strong VHL affinity and minimal off-target effects, enhancing the selectivity and efficiency of the PROTAC system.

Applications

ALV1 serves as a robust starting point for constructing VHL-recruiting PROTACs and targeted protein degraders. Researchers utilize ALV1 to design bifunctional molecules that degrade a variety of oncogenic and disease-driving proteins, accelerating early-stage drug discovery and biological validation efforts. Primary applications include:

• Synthesis of VHL-based PROTACs for targeted protein degradation studies
• Custom conjugation with diverse target ligands and linkers
• Structure-activity relationship (SAR) optimization and lead candidate identification in medicinal chemistry
• Expanding E3 ligand options for PROTAC platform development and mechanistic research in both academic and pharmaceutical settings

• High-purity compound verified by HPLC, NMR, and LC-MS
• Consistent batch-to-batch reproducibility with complete QC documentation
• Supplied with COA, MSDS, and analytical data for traceability
• Reliable global shipping with stability-guaranteed packaging
• Dedicated technical support and optional custom synthesis service
• Demonstrates strong binding affinity to CRBN, VHL, or other E3 ligases
• Enables stable E3 ligase recruitment for targeted protein degradation
• Optimized for high-affinity binding to VHL E3 ligase, enabling efficient target protein ubiquitination.
• Facilitates rapid development of potent and selective PROTAC molecules for advanced drug discovery projects.